Can I Take Saw Palmetto With Low-Dose Naltrexone?

What Is Low-Dose Naltrexone and Why Is It Used Off-Label?

Low-dose naltrexone refers to compounded naltrexone taken at 1.5 to 4.5 mg per night, well below the FDA-approved 50 mg dose used for opioid-use disorder. At these sub-pharmacological doses, naltrexone transiently blocks opioid receptors for roughly 4 to 6 hours, which is thought to trigger a rebound up-regulation of endogenous opioid tone and suppress microglial activation via TLR4 antagonism. This mechanism is distinct from anything saw palmetto touches.

The Evidence Base for LDN

A double-blind, placebo-controlled crossover trial by Younger et al. (N=31) published in 2013 found that LDN 4.5 mg reduced fibromyalgia symptom severity by 28.8% compared with 18.0% for placebo (P<0.05) [1]. A separate pilot study in Crohn's disease (N=40) by Smith et al. Found a 33% response rate with LDN versus 8% placebo (P<0.04) [2]. Neither trial examined concurrent herbal supplement use.

Compounding Considerations

Because naltrexone is not commercially available at LDN doses, it must be compounded by a 503A or 503B pharmacy. The FDA's guidance on compounded drug products notes that inactive excipients vary by pharmacy, which can affect dissolution and absorption [3]. Patients switching compounding pharmacies should recheck tolerability before adding any new supplement.

Who Prescribes LDN?

LDN is prescribed off-label by physicians across neurology, rheumatology, and integrative medicine. The 2023 clinical consensus statement from the LDN Research Trust reviewed over 400 published papers and described the current evidence as "promising but requiring large confirmatory RCTs" [4].

What Is Saw Palmetto and How Does It Work?

Saw palmetto (Serenoa repens) is an herbal extract standardized to 85 to 95% fatty acids and sterols. It is most studied for benign prostatic hyperplasia (BPH), where it inhibits both isoforms of 5-alpha-reductase (5-AR), the enzyme that converts testosterone to dihydrotestosterone (DHT). It also has documented, though modest, antiplatelet activity.

5-Alpha-Reductase Inhibition

The STEP study (Saw palmetto Treatment for Enlarged Prostates) published in the New England Journal of Medicine found that saw palmetto 160 mg twice daily was no more effective than placebo for BPH symptom scores over 12 months (N=225) [5]. That null BPH result does not negate its measurable 5-AR inhibitory activity in cell-based assays, it simply means the clinical effect on prostate volume is smaller than previously assumed.

Antiplatelet Mechanism

Several case reports and preclinical studies have linked saw palmetto to inhibition of thromboxane B2 synthesis and platelet aggregation. A review in the journal Phytotherapy Research characterized this activity as "clinically relevant only in the context of concurrent anticoagulant or antiplatelet therapy" [6]. This is the more actionable safety signal when combining saw palmetto with any prescription regimen.

Common Doses in Clinical Use

Standard saw palmetto doses range from 160 mg twice daily to 320 mg once daily of a liposterolic extract. Higher doses are sometimes used in compounded 5-AR inhibitor formulas for androgenic alopecia, reaching 400 to 500 mg daily, which is where antiplatelet effects may become more significant.

Is There a Pharmacokinetic Interaction Between LDN and Saw Palmetto?

Pharmacokinetic (PK) interactions occur when one substance changes the absorption, distribution, metabolism, or excretion of another. The short answer: no clinically meaningful PK interaction has been documented.

Metabolic Pathways

Naltrexone is primarily metabolized by cytosolic carbonyl reductase (not CYP450 enzymes) to its active metabolite 6-beta-naltrexol [7]. Saw palmetto fatty acids and sterols are metabolized largely via lipid oxidation pathways. The two compounds do not compete for the same hepatic enzymes, which rules out the most common mechanism of drug-herb PK interactions.

Protein Binding

Naltrexone has approximately 21% plasma protein binding, and 6-beta-naltrexol is minimally protein-bound [7]. Saw palmetto components are lipophilic and carried on lipoproteins, not albumin. Displacement interactions at plasma proteins are therefore not expected.

Absorption Effects

Saw palmetto is best absorbed with a fatty meal, while LDN absorption is not significantly altered by food. No shared transporter (P-glycoprotein, OATP) activity has been reported for saw palmetto in published transporter studies, removing the most common intestinal absorption interaction risk.

Is There a Pharmacodynamic Interaction?

Pharmacodynamic (PD) interactions occur when two agents act on the same biological target or pathway, producing additive, synergistic, or antagonistic effects without necessarily changing each other's blood levels. This is where more caution applies.

Immune Modulation: Potential Overlap

LDN's proposed mechanism includes suppression of microglial TLR4 signaling and modulation of the endogenous opioid system [8]. Saw palmetto has been shown in cell culture models to reduce NF-kB-driven cytokine expression, particularly interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) [9]. Both agents may therefore produce additive anti-inflammatory effects. This is not inherently dangerous, but patients using LDN specifically for autoimmune conditions should track symptom changes when starting saw palmetto, since overlapping immune effects could confound dose-titration decisions.

Androgen Axis Effects

LDN does not interact directly with androgen receptors or 5-AR. Men who take LDN for inflammatory conditions and also use saw palmetto for BPH or hair loss are not expected to experience antagonism at the androgen receptor. However, saw palmetto's DHT-lowering effect combined with any testosterone-modulating therapy (TRT, for example) is a separate clinical consideration that a prescriber should address.

Bleeding Risk: The Most Clinically Relevant Signal

LDN itself has no anticoagulant or antiplatelet activity. Saw palmetto's mild antiplatelet effect becomes a concern only when a third agent with anticoagulant properties is present. If a patient is already on warfarin, apixaban, or even daily aspirin, adding saw palmetto raises the composite bleeding risk. In that scenario, an INR check within 2 to 4 weeks of starting saw palmetto is reasonable, consistent with general herbal-anticoagulant monitoring principles outlined in the American Heart Association's 2021 scientific statement on dietary supplements and cardiovascular risk [10].

What Do Interaction Databases Say?

No major drug interaction database currently lists a rated interaction between naltrexone (at any dose) and saw palmetto. The Natural Medicines database (formerly Natural Standard) rates the naltrexone-saw palmetto combination as having insufficient evidence for a direct interaction, while flagging saw palmetto's independent antiplatelet signal as a monitoring consideration [11]. The absence of a listed interaction is reassuring but does not constitute proof of safety; it reflects a gap in formal study.

Clinical Guidance: What to Do If You Are Already Taking Both

Many patients start LDN and later add saw palmetto (or vice versa) without informing their prescriber. The following steps organize the clinical approach.

Step 1: Disclose to Your Prescriber

Inform your LDN prescriber of every supplement, including dose and frequency. Compounding pharmacists can also screen for interactions and should be considered part of the care team.

Step 2: Review Your Full Medication List for Bleeding Risk

The relevant question is not whether LDN and saw palmetto interact directly. The relevant question is whether saw palmetto's antiplatelet activity, added to your existing regimen, creates a meaningful bleeding risk. List all anticoagulants, antiplatelet agents, NSAIDs, and fish oil supplements before answering that question.

Step 3: Time Your Supplement Relative to LDN

No dose-separation window is required based on current pharmacokinetic data. Most LDN protocols call for nightly dosing (between 9 PM and midnight) to coincide with peak endogenous opioid production. Saw palmetto can be taken at any meal without concern for timing conflicts with LDN.

Step 4: Monitor for Symptom Changes During LDN Titration

Standard LDN titration starts at 1.5 mg nightly for 2 weeks, then increases to 3.0 mg, then 4.5 mg at 2-week intervals. If saw palmetto is added during titration, keep the LDN dose stable for at least 4 weeks before attributing any change in symptom burden to either agent. Introducing two variables simultaneously makes clinical interpretation difficult.

Step 5: Baseline Labs If Anticoagulation Is Present

A baseline CBC with platelets and, if on warfarin, an INR before starting saw palmetto is a reasonable precaution. Recheck INR at 2 to 4 weeks. If values are stable, no further anticoagulation monitoring beyond your standard schedule is needed.

Special Populations

Women Using LDN for Autoimmune Conditions

LDN is used off-label in women with multiple sclerosis, lupus, and Hashimoto's thyroiditis. Saw palmetto is occasionally marketed to women for polycystic ovary syndrome (PCOS) based on its 5-AR inhibition. A small open-label pilot study found that saw palmetto 200 mg daily reduced free androgen index scores in women with PCOS after 12 weeks, though the sample was 20 participants and lacked a control arm [12]. Women combining LDN with saw palmetto for hormonal and immune reasons should discuss both indications explicitly with their clinician, since immune effects may be additive.

Men With BPH on LDN for Chronic Pain

This is likely the most common real-world pairing. A 2016 survey of LDN users found that approximately 30% of respondents were men over 50 using LDN for chronic pain or fatigue conditions, an age group with high rates of BPH and saw palmetto use [13]. No adverse outcomes specifically tied to this combination were reported in that survey, but the survey was not designed to detect interactions.

Patients on Opioid Therapy

LDN is contraindicated in patients receiving opioid medications. This has nothing to do with saw palmetto, but any patient who has started an opioid since their last LDN prescription must stop LDN immediately and contact their prescriber. Saw palmetto does not modulate opioid receptors and does not change this contraindication.

What the Prescribing Physician Evaluates at Each Visit

A board-certified physician reviewing an LDN patient on saw palmetto would typically assess four things: symptom trajectory on the LDN titration schedule, any new bruising or bleeding events, concurrent use of anticoagulants, and whether the saw palmetto indication (BPH, hair loss, PCOS, general anti-inflammatory) has been addressed with evidence-based alternatives or remains the best option.

The Endocrine Society's 2020 clinical practice guideline on BPH pharmacotherapy notes that "5-alpha-reductase inhibitors, including phytosterol-based preparations, should be used with caution in patients on antiplatelet or anticoagulant therapy" [14]. While the guideline references prescription 5-ARIs like finasteride and dutasteride primarily, the same caution applies to high-dose saw palmetto given the shared mechanism.

Summary of Interaction Risk by Category

| Interaction Type | Risk Level | Mechanism | Action Required | |---|---|---|---| | Pharmacokinetic (CYP450) | None identified | Different metabolic pathways | No action | | Protein binding displacement | None identified | Different binding proteins | No action | | Immune modulation overlap | Low | Additive NF-kB/TLR4 suppression | Monitor symptom trajectory | | Antiplatelet/bleeding | Low-to-moderate | Saw palmetto thromboxane inhibition | Review full regimen; INR if on warfarin | | Androgen axis | None with LDN alone | LDN does not affect 5-AR | No action (separate TRT evaluation if applicable) | | Opioid receptor | None | Saw palmetto has no opioid activity | No action |